Portai, a Tel Aviv, Israel-based proteomics and AI-powered drug discovery startup, raised further $12M in Seed funding.
The spherical, which introduced the full quantity to $20M, was led by Grove Ventures and Pitango HealthTech and was joined by Maj Make investments Fairness Fund.
The corporate intends to make use of the funds to construct its oncology drug discovery pipeline, broaden information acquisition, in addition to enhance its discovery actions through pharma partnerships.
Based by Eran Seger and Kirill Pevzner, Protai empowers drug discovery and improvement with proteomic response biomarkers and synthetic intelligence to unlock new layers of organic insights and to fight advanced ailments. Since its preliminary funding final yr, the corporate has opened laboratories at its Israel R&D middle for information acquisition, organic validation and drug discovery actions and recruited an skilled drug discovery group with expertise in bringing medicine to the clinic. Moreover, Protai established collaborations with a number of main hospitals, and now has entry to over 100k well-defined banked samples for its complete tumor mapping course of, targeted on gyno-oncology and lung most cancers indications.
FinSMEs
15/03/2023
